Overcoming the suppressive activity of myeloid-derived suppressor cells may improve the efficacy of immune checkpoint inhibitors in treating melanoma.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Home News Late-Stage Melanoma: Experimental Drug Combo Puts 50% of Patients into Remission back to News
minute read
Overcoming the suppressive activity of myeloid-derived suppressor cells may improve the efficacy of immune checkpoint inhibitors in treating melanoma.
Topics: Press Coverage
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.